OncoMatch/Clinical Trials/NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Is NCT06899126 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Trastuzumab Deruxtecan and pembrolizumab for non-small cell lung cancer.
Treatment: Trastuzumab Deruxtecan · pembrolizumab · Pemetrexed · Chemotherapy — This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression
assessment of HER2 and PD-L1 expression by central or Sponsor-specified laboratory
Required: HER2 (ERBB2) mutation
Has no known HER2 mutation based on existing test results (if approved or validated local test is available)
Required: PD-L1 (CD274) expression
assessment of HER2 and PD-L1 expression by central or Sponsor-specified laboratory
Disease stage
Required: Stage IV, IIIB, IIIC
Prior therapy
Cannot have received: systemic anticancer therapy
Exception: adjuvant or neoadjuvant therapy (including ICI or platinum-based regimen) allowed if last dose ≥6 months before first trial dose and no progression on or within 6 months of last dose
Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Participants who received adjuvant or neoadjuvant therapy other than those listed below, including ICI (ie, anti-PD-1/PD-L1) or a platinum-based regimen, are eligible if the last dose of adjuvant/neoadjuvant therapy was given at least 6 months before the date of the first trial dose and should not have progressed on or within 6 months of the last dose date of adjuvant/neoadjuvant therapy.
Cannot have received: topoisomerase I inhibitor (including ADCs containing a chemotherapeutic agent targeting topoisomerase I)
Any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I.
Cannot have received: HER2-targeted antibody-based anticancer therapy
HER2-targeted antibody-based anticancer therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology & Hematology, LLC · Anchorage, Alaska
- Orange Coast Memorial Medical Center Fountain Valley · Fountain Valley, California
- California Research Institute · Los Angeles, California
- Los Angeles Cancer Network (LACN) · Los Angeles, California
- Providence Medical Foundation · Santa Rosa, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06899126 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 mutation is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV or IIIB or IIIC is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify